Chemomab Therapeutics (CMMB) Shares Outstanding (Diluted Average) (2021 - 2025)
Chemomab Therapeutics posted quarterly Shares Outstanding (Diluted Average) of $510.2 million for Q4 2025, up 42.11% year-on-year from $359.0 million in Q4 2024, and up 10.96% on a QoQ basis from $459.8 million in Q2 2025.
Chemomab Therapeutics (CMMB) has 5 years of Shares Outstanding (Diluted Average) data on file, last reported at $510.2 million in Q4 2025.
- For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 42.11% year-over-year to $510.2 million; the trailing twelve-month figure through Dec 2025 stood at $510.2 million (up 42.11% YoY), and the FY2025 full-year result was $510.2 million, up 42.11% from the prior year.
- Shares Outstanding (Diluted Average) for Q4 2025 stood at $510.2 million, up from $459.8 million in the prior quarter.
- Across five years, Shares Outstanding (Diluted Average) topped out at $510.2 million in Q4 2025 and bottomed at $207.5 million in Q4 2021.
- The 5-year median for Shares Outstanding (Diluted Average) is $228.1 million (2022), against an average of $275.4 million.
- The widest annual swing landed in 2023, when Shares Outstanding (Diluted Average) dropped 3.11%; it then surged 61.28% in 2025.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $207.5 million in 2021, then climbed by 9.7% to $227.6 million in 2022, then rose by 3.26% to $235.0 million in 2023, then surged by 52.79% to $359.0 million in 2024, then soared by 42.11% to $510.2 million in 2025.
- The last three Shares Outstanding (Diluted Average) figures came in at $510.2 million (Q4 2025), $459.8 million (Q2 2025), and $359.0 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.06 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 810.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 256.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 138.23 Mn |
| 10 | Chemomab Therapeutics | 959.23 Mn | 948.86 Mn | - | 510.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 510.23 Mn |
| Jun 30, 2025 | 459.83 Mn |
| Dec 31, 2024 | 359.05 Mn |
| Jun 30, 2024 | 285.11 Mn |
| Dec 31, 2023 | 235.00 Mn |
| Jun 30, 2023 | 221.67 Mn |
| Mar 31, 2023 | 221.00 Mn |
| Dec 31, 2022 | 227.59 Mn |
| Sep 30, 2022 | 228.77 Mn |
| Jun 30, 2022 | 228.17 Mn |
| Mar 31, 2022 | 228.09 Mn |
| Dec 31, 2021 | 207.47 Mn |
| Sep 30, 2021 | 227.96 Mn |
| Jun 30, 2021 | 216.27 Mn |